HER2-Negative Breast Carcinoma Clinical Trials in Atlanta, Georgia
5 recruitingAtlanta, Georgia
Showing 1–5 of 5 trials
Recruiting
Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled531 locationsNCT06058377
Recruiting
Not Applicable
Mobile Health for Adherence in Breast Cancer Patients
Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8+1 more
ECOG-ACRIN Cancer Research Group410 enrolled400 locationsNCT06112613
Recruiting
Not Applicable
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
Emory University150 enrolled4 locationsNCT06534125
Recruiting
Early Phase 1
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Emory University40 enrolled4 locationsNCT05464810
Recruiting
Not Applicable
A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Emory University30 enrolled4 locationsNCT05488145